The HDHD5 Knockout DLD-1 Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal population of DLD-1 colorectal adenocarcinoma cells with targeted disruption of the HDHD5 gene. This loss-of-function model enables systematic investigation of the HDHD5 protein, a predicted member of the haloacid dehalogenase (HAD) superfamily with putative phosphatase/hydrolase activity. The polyclonal format yields a heterogeneous pool of knockout cells, preserving population-level diversity while ensuring effective gene disruption, making it suited for bulk functional genomics and pooled screening applications.
The parental DLD-1 cell line originates from a human colorectal adenocarcinoma classified as Dukes’ type C, a clinically advanced and invasive tumor stage. Notably, DLD-1 cells exhibit microsatellite instability-high (MSI-H) driven by MLH1 promoter hypermethylation and consequent mismatch repair deficiency, alongside established oncogenic mutations in KRAS, APC, and TP53. These genetic hallmarks render DLD-1 a powerful model for colorectal cancer research, particularly for studies addressing genomic instability, altered signaling networks, and metabolic reprogramming in a therapeutically relevant context.
HDHD5 remains a poorly characterized enzyme, with no validated upstream regulators, downstream targets, or direct interaction partners reported. Structural homology places it within the HAD superfamily, suggesting a role in phosphoryl transfer reactions related to nucleotide metabolism, potentially within pyrimidine salvage pathways. Representative pathway components associated with this family include HAD superfamily hydrolases and nucleotide kinases. Mechanistic hypotheses propose that disruption of HDHD5 in DLD-1 cells may perturb pyrimidine homeostasis, thereby influencing processes such as DNA synthesis, proliferation, and metabolic stress responses, though the precise molecular consequences require experimental validation.
In the DLD-1 background, which carries oncogenic KRAS and p53 pathway defects along with MSI-H, HDHD5 deficiency provides a refined platform to probe metabolic vulnerabilities specific to colorectal cancer. The interplay between altered nucleotide metabolism and genomic instability creates a unique context in which HDHD5 knockout may modify growth phenotypes, apoptotic signaling, or sensitivity to chemotherapeutic agents. This model thus facilitates dissection of how a largely uncharacterized nucleotide-modifying enzyme integrates with established oncogenic pathways to impact cancer cell fitness.
Researchers can apply the HDHD5 Knockout DLD-1 Polyclonal Cells to a range of functional experiments, including Western blotting and RT-qPCR for target validation, proliferation and colony formation assays for growth phenotyping, nucleotide pool analysis for metabolic profiling, and apoptosis or drug sensitivity screens to assess therapeutic responses. The model is also relevant for exploring the molecular pathogenesis of cat eye syndrome, which involves duplication of the 22q11.1 region encompassing HDHD5. For technical assistance or additional information, please contact Ascent Research.
